Jagsonpal Pharmaceuticals Ltd.
BSE: 507789 | Sector: Health care |
NSE: JAGSNPHARM | ISIN Code: INE048B01027 |
BSE 12:51 | 07 Feb | 327.35 |
-0.95 (-0.29%) |
OPEN
330.95 |
HIGH
331.95 |
LOW
325.00 |
NSE 12:39 | 07 Feb | 327.40 |
-0.15 (-0.05%) |
OPEN
327.05 |
HIGH
331.85 |
LOW
324.05 |
OPEN | 330.95 |
PREVIOUS CLOSE | 328.30 |
VOLUME | 682 |
52-Week high | 420.20 |
52-Week low | 156.75 |
P/E | 41.59 |
Mkt Cap.(Rs cr) | 858 |
Buy Price | 327.00 |
Buy Qty | 101.00 |
Sell Price | 328.50 |
Sell Qty | 2.00 |
Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) - News Sector
-
Stay selective on defensives amid current market volatility: Analysts
12.51 pm | 7 Feb 2023 | Business Standard
Given the uncertainty on how the market trajectory may play out ahead, analysts believe investors can rotate allocation from high beta stocks to defen...
-
Stay selective on defensives amid current market volatility: Analysts
12.51 pm | 7 Feb 2023 | Business Standard
Given the uncertainty on how the market trajectory may play out ahead, analysts believe investors can rotate allocation from high beta stocks to defen...
-
P&G Health soars 15% after PAT jumps 71% YoY in December quarter results
11.17 am | 6 Feb 2023 | Business Standard
The management said that the higher PAT growth was supported by improved margin through portfolio premiumisation, healthy mix and optimization of expe...
-
Divi's Labs stock tanks 12% on big miss in Q3; near-term trend 'bearish'
12.21 am | 4 Feb 2023 | Business Standard
Analysts' average price target of Rs 3,862, however, indicates significant upside. The near-term trend remains bearish
-
Divi's Lab sinks 13%, hits 29-mth low as Q3 profit falls more than expected
2.26 pm | 3 Feb 2023 | Business Standard
In Q3FY23, Divi's Lab reported a 66 per cent year-on-year decline in its consolidated net profit at Rs 306.80 crore, on higher than expected in fall ...
-
Business initiative that has a heart: Lupin eyes Lyfe beyond the pill
6.59 pm | 2 Feb 2023 | Business Standard
Its digital health initiative for cardiac patients is part of its strategy to diversify into healthcare services
-
Sun Pharma Q3 net profit up 5.2% as sales grow in India, US markets
10.36 pm | 31 Jan 2023 | Business Standard
Company says specialty products will continue as growth driver, will scale up investment for it
-
Laurus Labs slips 5%, hits over 2-year low post December quarter results
3.13 pm | 31 Jan 2023 | Business Standard
Laurus Labs delivered operationally in-line performance, led by healthy traction in CDMO-Synthesis/Non-ARV API segment
-
Beside Adani Green, Adani Transmission; 14 other stocks hit new 52-week low
11.23 am | 31 Jan 2023 | Business Standard
Whenever a stock hits a new 52-week low, further fall from a medium-term scale appears realistic, with price endorsing further correction of 10 per ce...
-
Beside Adani Green, Adani Transmission; 14 other stocks hit new 52-week low
11.23 am | 31 Jan 2023 | Business Standard
Whenever a stock hits a new 52-week low, further fall from a medium-term scale appears realistic, with price endorsing further correction of 10 per ce...
-
Beside Adani Green, Adani Transmission; 14 other stocks hit new 52-week low
11.23 am | 31 Jan 2023 | Business Standard
Whenever a stock hits a new 52-week low, further fall from a medium-term scale appears realistic, with price endorsing further correction of 10 per ce...
-
Alkem launches novel antibiotic combination for drug-resistant infections
6.24 pm | 30 Jan 2023 | Business Standard
The formulation, to be sold under the Zidavi brans for Rs 2,700 a vial, has been approved by US FDA, European Medicines Agency, and CDSCO
-
Sun Pharma nears 52-week high ahead of Q3 results; stock up 7% in a month
11.56 am | 30 Jan 2023 | Business Standard
In the past one month, Sun Pharma outperformed market as shares surged 7 per cent, as compared to 2.5 per cent decline in the S&P BSE Sensex
-
Enzene Biosciences raises $50 million, aims to expand into global markets
12.22 am | 30 Jan 2023 | Business Standard
Enzene said it has built a highly experienced 400-person team under the leadership of Dr. Himanshu Gadgil, CEO at Enzene Biosciences Ltd
-
Flows to Indian equities are at risk as investors eye China: Chris Wood
10.55 pm | 27 Jan 2023 | Business Standard
He believes India remains the best long-term equity story in Asian and the emerging market (EM) context
-
Torrent Pharma Q3 PAT up 14% to Rs 249 crore riding on India, Brazil
10.45 pm | 25 Jan 2023 | Business Standard
Torrent Pharma's revenues came in at Rs 2,491 crore for the quarter under review. The Ebitda margins were at 29.1 per cent while gross margins were 71...
-
DRL posts strong 77% profit growth to Rs 1,247 cr riding on US, Russia
6.59 pm | 25 Jan 2023 | Business Standard
Firm says sustained focus on improving productivity has also helped boost profits; DRL is now bullish on its biosimilars and hopes to start filing for...
-
Torrent Pharma Q3 net profit up 14% to Rs 283 cr; interim dividend declared
6.26 pm | 25 Jan 2023 | Press Trust of India
Torrent Pharma on Wednesday said its consolidated net profit increased by 14 per cent to Rs 283 crore in the third quarter ended December 31, 2022. T...
-
Cipla Q3 net up 10% to Rs 801 cr, posts highest ever quarterly sales in US
5.44 pm | 25 Jan 2023 | Business Standard
Revenue up 6% to Rs 5,810 cr; firm expects US FDA audit at Goa unit
-
Lupin Digital launches Lyfe, a 24x7 monitoring ecosystem for heart patients
8.35 pm | 24 Jan 2023 | Business Standard
Company aims to onboard one million patients the platform, which aims to help them improve heart health through doctor-connected online and offline mo...
Quick Links for Jagsonpal Pharmaceuticals:
-
News
Announcements Brokerage Reports Business Earnings Sector -
Corporate Action
AGM Board Meetings Bonus Dividends EGM Rights Split -
INFORMATION
Bulk Deals Company History MF Holding Listing Info Locations Shareholding -
Financials
Financial Overview Balance Sheet Profit & Loss Cash Flow Ratios Quarterly Results Half Yearly Results Nine Monthly Results Yearly Results -
Annual Report
Auditors Report Chairman's Speech Company Management Directors' Report Finished Goods Raw Materials -
Peer Comparison
Competition Market Cap Price Price Performance Net Sales Net Profit Total Assets Historical Prices